<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03624192</url>
  </required_header>
  <id_info>
    <org_study_id>CTP006-1</org_study_id>
    <nct_id>NCT03624192</nct_id>
  </id_info>
  <brief_title>RES Prepared With RECELL® Compared to Conventional Care for Healing of Donor Sites in Ages 1-16 Years</brief_title>
  <official_title>A Prospective Multicenter Randomized Controlled Clinical Study to Investigate the Safety and Effectiveness of RES (Regenerative Epidermal Suspension) Prepared With the RECELL® Device Compared to Conventional Care for Healing of Donor Sites in Infants, Children and Adolescents (Aged 1-16 Years)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avita Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biomedical Advanced Research and Development Authority</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Avita Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate whether the time to complete closure is superior for RECELL-treated&#xD;
      split-thickness donor sites, compared with Control (standardized dressings only). The mean&#xD;
      time for donor site healing will be compared between treatments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study closed in response to COVID-19 and overall program objectives.&#xD;
  </why_stopped>
  <start_date type="Actual">September 19, 2018</start_date>
  <completion_date type="Actual">January 13, 2020</completion_date>
  <primary_completion_date type="Actual">January 13, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Each subject serves as their own control.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Complete Closure</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>The primary effectiveness endpoint is time, in days, to complete closure (≥95% epithelialization by blinded assessor) of study donor sites confirmed at two consecutive visits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Donor Site Treatment Preference (Site A or Site B) Reported by Subject</measure>
    <time_frame>4 weeks</time_frame>
    <description>Subject will be asked which donor site (A or B) they prefer (if subject is less than 8 years of age parents will be asked)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Site Treatment Preference (Site A or Site B) Reported by Physician</measure>
    <time_frame>4 weeks</time_frame>
    <description>Physician will be asked which donor site (A or B) they prefer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative Itching of Study Donor Sites Performed by Asking the Child Which Donor Site (A or B) Was Itchier After Treatment</measure>
    <time_frame>Day 7</time_frame>
    <description>Comparative Itching of study donor sites during 1st week post treatment by asking which site was itchier after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative Pain of Study Donor Sites Performed by Asking the Child Which Donor Site (A or B) Was More Painful Since Treatment</measure>
    <time_frame>Day 7 or 8</time_frame>
    <description>Comparative pain of study donor sites during 1st week post treatment by asking the child which site was more painful since treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blinded Evaluator Overall Opinion Score (1-10) Using the Patient and Observer Scar Assessment Scale (POSAS)</measure>
    <time_frame>Week 24</time_frame>
    <description>Blinded Evaluator Overall Opinion POSAS Score of study donor sites. The Overall Opinion Score uses a 10-point scale where 10 corresponds to the worst imaginable scar.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Overall Opinion Score (1-10) Using the Patient and Observer Scar Assessment Scale (POSAS)</measure>
    <time_frame>Week 24</time_frame>
    <description>Patient Overall Opinion POSAS Score of study donor sites(reported by subject 8 years of age or older, or by parent/guardian if subject less than 8 years of age). The Overall Opinion Score uses a 10-point scale where 10 corresponds to the worst imaginable scar.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Investigator's (Unblinded) Assessment of Healing at All RECELL-treated Areas by Direct Observation</measure>
    <time_frame>Through Week 52</time_frame>
    <description>Investigator's (unblinded) assessment of healing at all RECELL-treated areas including study donor sites by direct observation</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Subject Reported Pain Score Before and After Dressing Changes</measure>
    <time_frame>Up to Week 4</time_frame>
    <description>Mean subject (or parent/guardian) reported study donor site pain prior to and after dressing changes. Faces Pain Scale-Revised (FPS-R) or Numeric Rated Pain Scale will be used based on the child's age. Both scales use a 10-point scale where 10 is the worst pain imaginable or very much pain.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Subject Reported Study Donor Site Itching Score Prior to Dressing Changes</measure>
    <time_frame>Up to Week 4</time_frame>
    <description>Mean subject (or parent/guardian) reported study donor site itching score prior to dressing changes using the Itch Man Scale (0-4) where 4 represents itching most terribly</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Care Provider's Mean Pain Score Associated With Dressing Changes at Study Donor Sites</measure>
    <time_frame>Up to Week 4</time_frame>
    <description>Mean pain score associated with dressing changes at study donor sites assessed by the health care provider performing the dressing change using the Face, Legs, Activity, Cry, Consolability (FLACC) scale. The scale is scored in a range of 0-10 with 0 representing no pain.</description>
  </other_outcome>
  <other_outcome>
    <measure>Blinding Effectiveness by Asking the Blinded Evaluator Which Treatment They Think the Donor Sites (A and B) Received</measure>
    <time_frame>Week 4 and 24</time_frame>
    <description>Blinding effectiveness by asking the Blinded Evaluator which treatment they think the donor sites (A and B) received</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Skin; Deformity</condition>
  <arm_group>
    <arm_group_label>RECELL® Autologous Cell Harvesting Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RECELL + Telfa™ Clear and Xeroform™ dressings</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telfa™ Clear and Xeroform™ dressings</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telfa™ Clear and Xeroform™ dressings</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RECELL® Autologous Cell Harvesting Device</intervention_name>
    <description>Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings</description>
    <arm_group_label>RECELL® Autologous Cell Harvesting Device</arm_group_label>
    <other_name>RES (Regenerative Epidermal Suspension)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Telfa™ Clear and Xeroform™ dressings</intervention_name>
    <description>Telfa™ Clear and Xeroform™ dressings</description>
    <arm_group_label>Telfa™ Clear and Xeroform™ dressings</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients aged 1 through 16 years (inclusive) with a skin defect for&#xD;
             which autografting is indicated.&#xD;
&#xD;
          2. The area of total injury or planned defect (excluding donor sites) is 5% to 25% Total&#xD;
             Body Surface Area (TBSA), inclusive.&#xD;
&#xD;
          3. Two discrete donor sites of similar size (± 25%) can be created in a similar&#xD;
             non-articulating location (excluding the scalp) with each donor site representing a&#xD;
             minimum of 1% TBSA.&#xD;
&#xD;
          4. The patient and family member/parent/guardian are able to complete all follow-up&#xD;
             evaluations required by the study protocol.&#xD;
&#xD;
          5. In the opinion of the Investigator, the patient and/or parent/guardian must be able&#xD;
             to:&#xD;
&#xD;
               1. Understand the full nature and purpose of the study, including possible risks and&#xD;
                  adverse events, and&#xD;
&#xD;
               2. Provide informed consent/assent as appropriate for study participation.&#xD;
&#xD;
          6. The patient and/or parent/guardian agrees to abstain from any other treatment of the&#xD;
             wound(s) for the duration of the study unless medically necessary and comply with all&#xD;
             compulsory study procedures.&#xD;
&#xD;
          7. The patient and/or parent/guardian agrees to abstain from enrollment in any other&#xD;
             interventional clinical trial for the duration of the study.&#xD;
&#xD;
          8. The patient and/or parent/guardian can read and understand instructions and give&#xD;
             informed, voluntary, written consent.&#xD;
&#xD;
          9. Life expectancy greater than 52 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior autograft harvest at planned study donor sites.&#xD;
&#xD;
          2. Patients with sepsis or hemodynamic instability.&#xD;
&#xD;
          3. The patient has an infection under active management or other dermatologic condition&#xD;
             at the planned donor sites or treatment areas.&#xD;
&#xD;
          4. Patient (of reasonable age) or parent/guardian is unable to follow the protocol&#xD;
             requirements.&#xD;
&#xD;
          5. The patient has other concurrent conditions that in the opinion of the Investigator&#xD;
             may compromise patient safety or study objectives.&#xD;
&#xD;
          6. Patients with a known hypersensitivity to trypsin or compound sodium lactate for&#xD;
             irrigation.&#xD;
&#xD;
          7. In post-pubescent girls, pregnant or breast-feeding (pregnancy test should be&#xD;
             performed in accordance with local institutional requirements).&#xD;
&#xD;
          8. Enrollment in a concurrent study in which the study treatment may confound the&#xD;
             endpoints of this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arizona Burn Center at Maricopa Intergrated Health Systems</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shriners Hospital for Children, Northern California</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shriners Hospital for Children, Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Regional Burn Center at Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <results_first_submitted>July 7, 2021</results_first_submitted>
  <results_first_submitted_qc>July 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 28, 2021</results_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric, Complex Skin Deformities</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Skin Abnormalities</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT03624192/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Every subject received both interventions (RECELL and CONTROL) such that each subject served as their own control.&#xD;
RECELL + Telfa™ Clear and Xeroform™ dressings&#xD;
RECELL® Autologous Cell Harvesting Device: Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings&#xD;
Telfa™ Clear and Xeroform™ dressings: Telfa™ Clear and Xeroform™ dressings</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RECELL</title>
          <description>Every subject received both interventions (RECELL and CONTROL) such that each subject served as their own control.&#xD;
RECELL + Telfa™ Clear and Xeroform™ dressings&#xD;
RECELL® Autologous Cell Harvesting Device: Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings&#xD;
Telfa™ Clear and Xeroform™ dressings: Telfa™ Clear and Xeroform™ dressings</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>very subject received both interventions (RECELL and CONTROL) such that each subject served as their own control.&#xD;
RECELL + Telfa™ Clear and Xeroform™ dressings&#xD;
RECELL® Autologous Cell Harvesting Device: Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings&#xD;
Telfa™ Clear and Xeroform™ dressings: Telfa™ Clear and Xeroform™ dressings</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental: All Participants (Within Patient Control)</title>
          <description>All subjects receive both RECELL and Control. Each subject serves as their own control.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.7" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Complete Closure</title>
        <description>The primary effectiveness endpoint is time, in days, to complete closure (≥95% epithelialization by blinded assessor) of study donor sites confirmed at two consecutive visits.</description>
        <time_frame>up to 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RECELL</title>
            <description>Every subject received both interventions (RECELL and CONTROL) such that each subject served as their own control.&#xD;
RECELL + Telfa™ Clear and Xeroform™ dressings&#xD;
RECELL® Autologous Cell Harvesting Device: Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings&#xD;
Telfa™ Clear and Xeroform™ dressings: Telfa™ Clear and Xeroform™ dressings</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Every subject received both interventions (RECELL and CONTROL) such that each subject served as their own control.&#xD;
RECELL + Telfa™ Clear and Xeroform™ dressings&#xD;
RECELL® Autologous Cell Harvesting Device: Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings&#xD;
Telfa™ Clear and Xeroform™ dressings: Telfa™ Clear and Xeroform™ dressings</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Complete Closure</title>
          <description>The primary effectiveness endpoint is time, in days, to complete closure (≥95% epithelialization by blinded assessor) of study donor sites confirmed at two consecutive visits.</description>
          <units>Days</units>
          <param>Number</param>
          <units_analyzed>Site</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Site</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subject 001</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 003</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 004</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Donor Site Treatment Preference (Site A or Site B) Reported by Subject</title>
        <description>Subject will be asked which donor site (A or B) they prefer (if subject is less than 8 years of age parents will be asked)</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Treatment: RECELL + Telfa™ Clear and Xeroform™ dressings. RECELL® Autologous Cell Harvesting Device: Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings&#xD;
Control: Telfa and Xeroform only</description>
          </group>
        </group_list>
        <measure>
          <title>Donor Site Treatment Preference (Site A or Site B) Reported by Subject</title>
          <description>Subject will be asked which donor site (A or B) they prefer (if subject is less than 8 years of age parents will be asked)</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RECELL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Donor Site Treatment Preference (Site A or Site B) Reported by Physician</title>
        <description>Physician will be asked which donor site (A or B) they prefer</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Treatment: RECELL + Telfa™ Clear and Xeroform™ dressings. RECELL® Autologous Cell Harvesting Device: Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings&#xD;
Control: Telfa and Xeroform only</description>
          </group>
        </group_list>
        <measure>
          <title>Donor Site Treatment Preference (Site A or Site B) Reported by Physician</title>
          <description>Physician will be asked which donor site (A or B) they prefer</description>
          <units>Physician Response</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RECELL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to determine/no preference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparative Itching of Study Donor Sites Performed by Asking the Child Which Donor Site (A or B) Was Itchier After Treatment</title>
        <description>Comparative Itching of study donor sites during 1st week post treatment by asking which site was itchier after treatment</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Treatment: RECELL + Telfa™ Clear and Xeroform™ dressings. RECELL® Autologous Cell Harvesting Device: Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings&#xD;
Control: Telfa and Xeroform only</description>
          </group>
        </group_list>
        <measure>
          <title>Comparative Itching of Study Donor Sites Performed by Asking the Child Which Donor Site (A or B) Was Itchier After Treatment</title>
          <description>Comparative Itching of study donor sites during 1st week post treatment by asking which site was itchier after treatment</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RECELL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No difference/Can't tell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparative Pain of Study Donor Sites Performed by Asking the Child Which Donor Site (A or B) Was More Painful Since Treatment</title>
        <description>Comparative pain of study donor sites during 1st week post treatment by asking the child which site was more painful since treatment</description>
        <time_frame>Day 7 or 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Treatment: RECELL + Telfa™ Clear and Xeroform™ dressings. RECELL® Autologous Cell Harvesting Device: Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings&#xD;
Control: Telfa and Xeroform only</description>
          </group>
        </group_list>
        <measure>
          <title>Comparative Pain of Study Donor Sites Performed by Asking the Child Which Donor Site (A or B) Was More Painful Since Treatment</title>
          <description>Comparative pain of study donor sites during 1st week post treatment by asking the child which site was more painful since treatment</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RECELL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Pain at Either Donor SIte</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Difference/Can't Tell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blinded Evaluator Overall Opinion Score (1-10) Using the Patient and Observer Scar Assessment Scale (POSAS)</title>
        <description>Blinded Evaluator Overall Opinion POSAS Score of study donor sites. The Overall Opinion Score uses a 10-point scale where 10 corresponds to the worst imaginable scar.</description>
        <time_frame>Week 24</time_frame>
        <population>Data was not collected for subject 001</population>
        <group_list>
          <group group_id="O1">
            <title>RECELL</title>
            <description>Every subject received both interventions (RECELL and CONTROL) such that each subject served as their own control.&#xD;
RECELL + Telfa™ Clear and Xeroform™ dressings&#xD;
RECELL® Autologous Cell Harvesting Device: Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings&#xD;
Telfa™ Clear and Xeroform™ dressings: Telfa™ Clear and Xeroform™ dressings</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Every subject received both interventions (RECELL and CONTROL) such that each subject served as their own control.&#xD;
RECELL + Telfa™ Clear and Xeroform™ dressings&#xD;
RECELL® Autologous Cell Harvesting Device: Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings&#xD;
Telfa™ Clear and Xeroform™ dressings: Telfa™ Clear and Xeroform™ dressings</description>
          </group>
        </group_list>
        <measure>
          <title>Blinded Evaluator Overall Opinion Score (1-10) Using the Patient and Observer Scar Assessment Scale (POSAS)</title>
          <description>Blinded Evaluator Overall Opinion POSAS Score of study donor sites. The Overall Opinion Score uses a 10-point scale where 10 corresponds to the worst imaginable scar.</description>
          <population>Data was not collected for subject 001</population>
          <units>Score on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subject 001</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Subject 003</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 004</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Overall Opinion Score (1-10) Using the Patient and Observer Scar Assessment Scale (POSAS)</title>
        <description>Patient Overall Opinion POSAS Score of study donor sites(reported by subject 8 years of age or older, or by parent/guardian if subject less than 8 years of age). The Overall Opinion Score uses a 10-point scale where 10 corresponds to the worst imaginable scar.</description>
        <time_frame>Week 24</time_frame>
        <population>Data was not collected from subjects 001 and 004</population>
        <group_list>
          <group group_id="O1">
            <title>RECELL® Autologous Cell Harvesting Device</title>
            <description>RECELL + Telfa™ Clear and Xeroform™ dressings&#xD;
RECELL® Autologous Cell Harvesting Device: Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings</description>
          </group>
          <group group_id="O2">
            <title>Telfa™ Clear and Xeroform™ Dressings</title>
            <description>Telfa™ Clear and Xeroform™ dressings&#xD;
Telfa™ Clear and Xeroform™ dressings: Telfa™ Clear and Xeroform™ dressings</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Overall Opinion Score (1-10) Using the Patient and Observer Scar Assessment Scale (POSAS)</title>
          <description>Patient Overall Opinion POSAS Score of study donor sites(reported by subject 8 years of age or older, or by parent/guardian if subject less than 8 years of age). The Overall Opinion Score uses a 10-point scale where 10 corresponds to the worst imaginable scar.</description>
          <population>Data was not collected from subjects 001 and 004</population>
          <units>Score on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subject 001</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Subject 003</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 004</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Investigator's (Unblinded) Assessment of Healing at All RECELL-treated Areas by Direct Observation</title>
        <description>Investigator's (unblinded) assessment of healing at all RECELL-treated areas including study donor sites by direct observation</description>
        <time_frame>Through Week 52</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Subject Reported Pain Score Before and After Dressing Changes</title>
        <description>Mean subject (or parent/guardian) reported study donor site pain prior to and after dressing changes. Faces Pain Scale-Revised (FPS-R) or Numeric Rated Pain Scale will be used based on the child's age. Both scales use a 10-point scale where 10 is the worst pain imaginable or very much pain.</description>
        <time_frame>Up to Week 4</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Subject Reported Study Donor Site Itching Score Prior to Dressing Changes</title>
        <description>Mean subject (or parent/guardian) reported study donor site itching score prior to dressing changes using the Itch Man Scale (0-4) where 4 represents itching most terribly</description>
        <time_frame>Up to Week 4</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Health Care Provider's Mean Pain Score Associated With Dressing Changes at Study Donor Sites</title>
        <description>Mean pain score associated with dressing changes at study donor sites assessed by the health care provider performing the dressing change using the Face, Legs, Activity, Cry, Consolability (FLACC) scale. The scale is scored in a range of 0-10 with 0 representing no pain.</description>
        <time_frame>Up to Week 4</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Blinding Effectiveness by Asking the Blinded Evaluator Which Treatment They Think the Donor Sites (A and B) Received</title>
        <description>Blinding effectiveness by asking the Blinded Evaluator which treatment they think the donor sites (A and B) received</description>
        <time_frame>Week 4 and 24</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Experimental: All Participants (Within Patient Control)</title>
          <description>Every subject received both interventions (RECELL and CONTROL) such that each subject served as their own control.&#xD;
RECELL + Telfa™ Clear and Xeroform™ dressings&#xD;
RECELL® Autologous Cell Harvesting Device: Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings&#xD;
Telfa™ Clear and Xeroform™ dressings: Telfa™ Clear and Xeroform™ dressings</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Graft Loss 135cm2</sub_title>
                <description>Graft loss due to shearing of a non-study site</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP, Clinical Research</name_or_title>
      <organization>AVITA Medical</organization>
      <phone>661-367-9170</phone>
      <email>USClinicalTrials@avitamedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

